<SEC-DOCUMENT>0000886163-15-000040.txt : 20150423
<SEC-HEADER>0000886163-15-000040.hdr.sgml : 20150423
<ACCEPTANCE-DATETIME>20150423160629
ACCESSION NUMBER:		0000886163-15-000040
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150423
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150423
DATE AS OF CHANGE:		20150423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		15788511

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgnd_form8-krehermanxdesil.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>LGND_Form8-KreHerman_deSilvaCFOtransitionApr2015</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sCE96B37F730886C3051CE723143B02EF"></a><div></div><br><div style="line-height:120%;padding-top:5px;text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8&#8209;K</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported): April [24], 2015</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77-0160744</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11119 North Torrey Pines Road, Suite 200</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92037</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s66081778878D0559FC19E723145BDCBC"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 23, 2015, Nishan de Silva, the Company&#8217;s Vice President, Finance &amp; Strategy and Chief Financial Officer, announced his resignation, effective May 20, 2015.  </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 23, 2015, the Company named Melanie J. Herman to the role of interim Chief Financial Officer, effective on May 21, 2015.  Ms. Herman, 36, currently serves as the Company&#8217;s Director of Accounting and Chief Accounting Officer, roles she assumed in March 2014 and April 2014 respectively.  She joined the Company in January 2011 and served as the Company&#8217;s Controller until her promotion to Director of Accounting in March 2014.  Previously she was Controller at CyDex Pharmaceuticals, Inc. from 2009 to 2011, Assistant Controller and Accounting Manager at Entertainment Properties Trust from 2004 to 2009, and Senior Accountant at KPMG, LLP from 2001 to 2004.  Ms. Herman holds a Bachelor of Science with a dual major of Accounting and Finance from Kansas State University and is a Certified Public Accountant (inactive).  Ms. Herman will continue to maintain responsibility for the Company&#8217;s accounting functions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has issued a press release regarding Dr. de Silva&#8217;s departure and Ms. Herman&#8217;s appointment, a copy of which is filed as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d) Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="2%"></td><td width="90%"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated April 23, 2015.</font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="s66081778878D0559FC19E723145BDCBC"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="45%"></td><td width="5%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: April 23, 2015</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Charles Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, General Counsel and Secretary</font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="s66081778878D0559FC19E723145BDCBC"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="2%"></td><td width="90%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated April 23, 2015.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>melaniehermannamedinterim-.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>MelanieHermannamedinterim-CFO</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sFD8D34A6DEFB54017F84E76A1889CDCD"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:left;"><img src="melaniehermannamedint_image1.gif" style="height:38px;width:109px;"></div><div style="line-height:120%;text-align:left;text-indent:160px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ligand Pharmaceuticals Incorporated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LHA</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">John Higgins, President and CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bruce Voss </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">investors@ligand.com &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;bvoss@lhai.com </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(858) 550-7500&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(310) 691-7100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">@Ligand_LGND&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;@LHA_IR_PR</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Names Melanie J. Herman Interim Chief Financial Officer</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SAN DIEGO (April 23, 2015) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) </font><font style="font-family:inherit;font-size:11pt;">announces the appointment of Melanie J. Herman as interim Chief Financial Officer, effective May 21</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:11pt;">.  Ms. Herman currently serves as Ligand&#8217;s Director of Accounting and Chief Accounting Officer.  She succeeds Nishan de Silva, who has accepted the position of President and Chief Operating Officer at a privately held therapeutics-focused gene editing company and who has notified Ligand of his resignation, to be effective next month.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Melanie has been a highly competent and dedicated colleague for more than four years at Ligand, joining the team when we acquired CyDex and the Captisol business.  She is well-versed in all aspects of our accounting and finances, and is particularly knowledgeable about our Captisol business having worked at CyDex prior to Ligand&#8217;s acquisition of the company,&#8221; said John Higgins, Chief Executive Officer of Ligand.  &#8220;It has been a pleasure working with Nishan, and on behalf of Ligand and our Board of Directors I extend best wishes to him for continued professional success.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ms. Herman joined Ligand in January 2011 as the Company&#8217;s Controller, and was named Director of Accounting in March 2014 and Chief Accounting Officer in April 2014.  Previously she was Controller at CyDex Pharmaceuticals, Inc. from 2009 to 2011, Assistant Controller and Accounting Manager at Entertainment Properties Trust from 2004 to 2009 and Senior Accountant at KPMG, LLP from 2001 to 2004.  Ms. Herman holds a Bachelor of Science with a dual major of Accounting and Finance from Kansas State University, and is a Certified Public Accountant (inactive).</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Ligand Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand&#8217;s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer&#8217;s disease, dyslipidemia, anemia, asthma and osteoporosis.  Ligand&#8217;s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen Inc., Merck, Pfizer, Baxter International and Eli Lilly &amp; Co.  Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Follow Ligand on Twitter @Ligand_LGND.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sFD8D34A6DEFB54017F84E76A1889CDCD"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. These statements include those related to Company&#8217;s personnel and executive officer transitions. Actual events or results may differ from our expectations. For example, there can be no assurance that Ms. Herman will be able to take on the role of interim Chief Financial Officer on the expected timeline or at all. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via www.ligand.com as well as in Ligand's public current and periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>melaniehermannamedint_image1.gif
<TEXT>
begin 644 melaniehermannamedint_image1.gif
M1TE&.#EAQ@4+`O<```````````$!`>1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P
M'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'G%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q=')R=7)R=7-S=G1T=W=V>7IZ?']_@(:&AXN+C)"0
MD)&1D9*2DI.3DY24E)65E9:6EI>7EYB8F)>:FY>;G9:<GY:=H):>H9>>H9>?
MHIB@HYJ@HYZBHZ"CI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^
MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-
MS<[.SL_/S]#0T-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<
MW-W=W=[>WM_?W^'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOKZ^SL
M[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ^OO[
M^_S\_/W]_?[^_O_______R'Y!`$`````+`````#&!0L"0`C^``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSYL(G.'/JW/G$IL^?0(,*'4JTJ-&C2),J7<JTJ=.G4)ORG$JUJM6J
M0Z]2U!JUJ]>O8,.*'4NVK-FS:-.J76OQJMNW<&U2/0AW;D&L;//JW<NWK]^_
M@`,+'DP8:MW#B''2M$N7IT&\C1T#2$R9:^'+F#-KWLRYL^?/H,56'@TY9FF"
M4R/O1$BZ]>'0L&/+GDV[MNW;N,NZWMU3;NG4K.=:'<B;=^[CR),K7\Z\N?/8
MQ5L7C<Y8-77*S[-KW\Z]N_?OX$?^7J^\>?SH\.C3JU_/OKW[R^83EX\O_[W]
M^QX9Z-_/O[___P#RA]^`!!:(''VO:88@8@8VZ*!``48HX804,O#@A1AFR-:"
M<2G(88<:AHA>A2262**(**:HXE$?NC5?BY:M*.-R)M9H(X`SYJCCCB?!.)R'
M/I[&XY"PW6CDC40FJ>22$`59'7Q./LGDE)<=:66%5&:II9)12I99E\!M*:9@
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MGZ@=^G"O4*Z<;Z3``DVSO2+GK)+2@^W,,W$EB]1Q:$)/7'5M&Q_-,)-1H[NU
MJR$_?1?3)#&:F\0L^^S<U4&3/637XB%=]-=/P^V1W53C;2K^VMKI[:C?*@)^
MM]P@PRAV<$[WZ#9M@F_$]W:-QZNVIHM[37C;81\^=N*6<H[;Y$N#KFCE?#W.
M->F6T]U7Y#9[7C;JT,'NN.BCNPZ8Z>#*_KKN!M,.-L:>ML1ZX3Z2/#S6O*N%
M.Y?)[[[\OF;_#;R\PC??V?$1/=^W]6=I_S;WG;\\=-:D3F^^D(K;;AOV3?K>
M'?L>P^^@_*F?[VY7]N>?,DKT-PV^1-Y[3O^\$L`=#7!P^IL9].[',?6%Y("W
M^U_VW,<=""[0@0:4(`(3N*SRJ4IF&IP@!F=C0<2%$#8E=$H!=91"A]B+@Y_2
M#;\PT\+'G-!;ETM?#8UUP][MD#W^/[1.BR["P`BNT(@YU*'J;A-$;AWQ0#TD
M(`63U$0G!DES/:OB4ZJH1<F-<&]39$X781;&[WV1(]'"HA6CZ,4DAF^)ZV.C
M"]F6JC*"<(S?:6+F#F='K3W*>&=$H1P?0K3CQ.QW;F1>(#6"1_<\46=]_$@C
M_S7(]A6R8N/R8QHIMTA&?I!*=/1?\`"9R,]5$H#B^TO+-/E'3I;RC3`TFA1#
MJ3Q?5:^3GYFD$&<H0^JQ\HI)PR488WD^J_$2?]JZY2OC*$S^91(I'"0>,8N9
M$ETF9)JQ7(DLTT9-;9ZR=-^<73+1:+0]\A";Q'1F,W^&SOS!LIV%W&3HUBG-
M(:H0GH?^W&6E?HG/CRG1G#[IIT`S)K6!%N^:K9SG,I%'3]\85%*\DB?F'HHQ
M=2[4HI&,'[,P2M&!B?"@WFPH(B7:RXXJK",`G:A)LZ50.!8THR.E937Q^5*0
MMC2E9PMG5M`94F"JL4#-FLDC22C3\<W***Y1UFX&5"N5`>R"#/JI5/])TMJ)
M=*I8S:I6M[JFJS)1IUP-JUC'2M;D@)4SUBRK6M?*UK::S*L,A:M;YTK7NMKU
MK1>M8UKORM>^^O6O/=VK!XL*V,(:]K"(5>HH<SFUQ#KVL9"-+,)6J;%G2?:R
MF,VL9I6Y4FQN]K.@#:UH:]I97X[VM*A-K6K%6=K%KO:UL(W^K6PEV=JESO:V
MN,VM;OLUSMWZ]K?`#:YPATO<%=F41?$IKG*7R]S#"A9]1)12<Z=+W>I*59?0
M#=/FX+7=;<W1H]8-KWC':Q_L:K>[=;E)/LG+WO:ZEZAR;8MTSPLU.JWQ5T-]
MKW[WRU].G960/]I*@.O[W_X:^,`(QEF!,4*:C\8WP1".L(1O6E51+GC"&,ZP
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M+?.:/NURM;/.'&M/HS=Z'G9M0,D'35MN^HJ??""T*#GG^L&SGK5V):`#*^N*
MD%JHV4;BM]DYO:3@^M#15BSPL&U/;4N:V^^F]IVEPV=8H_1=ME)VJ8^9[W2Q
M>Y_NKC`IM^U?85^(L-;>)CB1K6=[R]O9,14X%:-L;#/G]5X&/[:^57IQCG9[
MV>GFN,3^B=3(C`^;X!A'.3G'G3=B#_/CYF:YJCLN(SR:_-4T#[BI9UIQG)?<
MX8*\>:1AGE.A$WCD,]\Y'PM,]&9W&.'*:3J%X\W"'AM]Z"H/9LX]>?62;IWK
M/7\XU1TM=69^?8-CEU[6M;YV!H<=W6V/;ME1?/8V=MVJ<4=[VKV>=S?O>>![
M;WG=O>WR>O>=[X?'T',+K^Z[6_S7O08\TN.:^$D[?N&#[_?;39SYN#&\@3+W
M(>0K[^#`8S+C0#<[Z<.2^@S!7.$>9_:,1\]OJBK=D&=M/>,VOVC3%_OR`*9]
MJ.$N_)#'7M=1SSWC5>_[@O.^Z)TG;?$I1G?8:W3UP8\^#97^O_S=`Q_DSS?E
M]X,]_:`.MO9(OOG<L8[]4Z]?U+<7C.X/;G5(3S,OH3=R\^6N?9$?]_B3EVC]
MQWK=IW@7%H"!-GYP%GZ/UW[NYX!V!H$<5H"")X'PAX!RPG3QUR?SIW;[)U\*
M.$L#6'HA*'88Z&L,R'PGR%KAICD4B((6V&HCF'0;:'LQB'D=2(#OIV;<]X%F
M5(+[YH,"!H07^'^]1X0+N%[GE(*4)X2?EH.N]X*:!X7?-8/RUV4;IW_GYG_(
MUS`+)E#@\7EW9'PV:(2XIX"RYX&6Y7<`USI62(+EUX8^EG^B)RQ':(;0=X,@
MV%BSMV9L&(==6(8M"&Z`*(8\IX3^R69:4Q>(9_B&>O=,W)1.?UB(-?B(E?AL
ME%A#+`5VUR9YE^A]CBA]F=A@&I=FDSB*@RB*GTB(J)B%]]:*0K*"+.B$VX>$
M50B+E:9>JTAVN*B)GH9^A#=Z[T1[V9>*P\B(>4B+X$>,;K>+O-B+>GA?RCB$
M4OAGD`B`!C6+<HB-[2:`T6A,)N4\>'B*T'@>=VB*\#:-5VB(D3@OZ9A<D/*-
MSXB,Z^B'K+B-8T:.XQ$>5,A;YIB/U_5F``E8.RB"\CB0")F0=1.*0<>0"OF0
M$*DFMHA7#AF1%GF1N3.1W5.0&-F1'IE'U<AC(?F1)%F2/PAUC`6,)KF2+,DS
M$)=^6]C^DC(YDR[83GN80#29DSJY5>7HBCOYDT"I53V)CT%9E$9I5T,Y8$>Y
ME$RI6GW6E%`9E5(YE51I>/]HD%=9E5JYE7=5D<V8)Z68BUPYEF0IE+\(77"H
M+F6YEFPI-GMU&JQ6BFTYEW0Y)M8D7>2GED<GEFA9EW[YEX&S97B9EXFB<2;D
M78"9F(H9A9<WF'%YF'I)F*.RF)19F2GIE1,HEGL)7EFDDI;YF:!)D>IXDY&Y
MF9!9F)O9$_T8FJS9FOYXD+IH7Y(I@]N"%ZOIFKB9FPJ&ADH9C.=UF[H9G,(I
MCJ.Y<KUYFK(IC;`YG,S9G$^XG-1H?K2)F<Y9G=:9F=`9A-G^>9W<:9T<J8JR
MV)WB.9X1I9&>&)[DF9[J.9WHZ7SFN9X*P6+P"9'?*6WU69U@%F;SF67W66A,
MR)WY62/[Z63]:8GM.:`B$:!(@J!`5J"O^)_.J:!VPJ`ZYJ#&^9[7*:%'0J$U
M9J':6)P<&A$:.J$A6F(>RHG46:(&,:(DJJ(:=J()"*',R:(VXJ(D!J-?B:'6
M2:,":J,;AJ/\IZ,[RJ,GXJ,O*J/$N9TN2J048J0_BJ2>!Z4SRJ0XXJ1/*J2"
M.(Y66A)4FF-;"F)`2II*^I!9^14!>IFIAEM1A5B-!GICVG`@.B/[HU<O676]
M)7Y@27R>>9(^N8A:"F5ANH3T&('^YG,?V2ANZ-B`FQ@B]IBE1%F/6&II;TIN
MA"9&MU9+!QJ=^O,>/&6?*>IT4GIZGTJICU:!E&B-F8J=8`@Y*W6A<5J$@\JG
MJ9J$S(BH24E0>MJ-*-I:9C5J8NJ,^#>2!.*@O2B:MWJ<M@:LN_9K/%BKM_BJ
M6R2L3!6JQXJK?5BM;<I^?SIKPOAOS!J;D_J:HSIH,HJMF`:JYFI;B;BMRIF)
M-`B+W&J,D#JN_,B$Z9JGM'JOZ@JGC]JNQ8J#U9J:L3J&D=JL]%J>=>JJ!;.N
M^AH=_)JH`IN4:MBP!9NDT%I>FW=4F-BG[<B']W@PRPA2":NJBXJJ=XJPX:B/
MYI%R%QO^I"@9LB_[CN$:HV1(JC"TFR,;K2!KLVT6<<H:F$"XIS''CO'XL]=*
MM.>Y;G-8LR>GL=I9;BJ[CVS7LL\9JGX2L\?85#[K>(6:JTC[M'28K/ZTM>QJ
MIP>+G+,ZM/.FM0T)G,]ZLEB)M02#B.<'MUI(M>V15M*JK6FKL/BJ@F?K;Y@:
MMN#XM8@79V0KKQ,'?('ZMD:;.B"YMR2;L^[IMC0KMX>[L+5HM7-SMA&KN`#[
MN!GY='8XKX@FM#"IN5Q8MAG(M14+GJ`KD9)[M==XMS/;F98;MW1KNG@+1!3G
MN4O;N_1W@$R[NJS+C:(+J+M+J+?;:7?WN@EWO%,KO)\+O3+^F[P&2KTF.+MN
M"KP55'_-"[,#FR9:A+K>.GQ%R[TPV+@HZ[VLVG76&[VQ*[M"E[N#"[R&FXS:
MR[?[6Z_PZ[[Y*KW3.[XOU[^92\"PV[?7P[G9B\!R2F/Q:['S2[^CRK[(VZ^.
MJJMX!L`;:\"1&[@<G&O8.[K+:<$7C+[7*\!6J<`ZR,`BZ;D1[*DLS"-<Y,(?
M.\.6%\-@J\+W&\)K`[X>S+`.;)<:J,,WC,..B\0O'+Y'K,33ZKI,K*@C3,+:
M:\(9#+$GC,7?:\0?ZL3X,4E6#*Y!/"E%[,/55\7J*ZAC+,)1[(UK',9HR\.6
MNJHIC,&`.\2[NL;KZ\4Z:\-1Z[#^<\O%.:S'35M\YZC!G`>;]FN\6ORN4SR\
M'+S(3<S'A=R3AVS'34C)RVK&E:O)/N?'B=O('4O(!0S*DYNNERS*>'J0DJS&
MGES);9Q\)6B^_&O*N$NQ@RG!<KS`J)?&C(S"MOO(#R)K'"NN^=N]N'Q2=:S*
M*RS,2>S,;4O*A1O+O3J13AO(:0BKR:S,?CK!DBJ\K1S,WCR/U)S(TDR[.^NW
MM8O,VTR*RPS,C<C*ONS*T%R'G.S&KZS.^GK&[2R=60QL="K/<"S%]:R[^;P>
M1-?/I0G+FXK-:"S(H[S+FEK.VXO'QGK.`8W1MXS+_)S.!BW1ODG1#&W1+GO/
M4ZC1$4W^TET5M/W\T<5<MP?MKR#]QVS[SY/IOR;-LP4]K)S6SBW\TANI?K:L
MT^.LSRK=S$<=U$,MSHA,U$-YP!`=T@^=T^R<U!,MTC"]TT<;T^D!QNQ2J78W
MSVI;PDN=RO`LOUI]OO`8RI@L9TJZ;=VTQU'=Q3/=OES=R6G-GECMTDW-NW>-
MT]O)PM;'O'N=OF0]US@+G9B+U'5MLHCMR$7]H)&MR\C*V'G]TU-=V&*[OXM]
MQXU]?50=SYG=UQPHUEO]V8-\V:&KVG',VGZ-VEG]UV%8QJ1=VF7MGX<=VB,-
MVVDIVQ/KVHVGV:"HR,!M@`-=TL4MTY,MJH%]S,-]VW:-TK+^_*F^S=/0W<"U
MG<#9G<G)'9;2O=NZ_<[,+*O%'=[O^]BEW-W'':5C2LLT/=X$:]Z>O=S(S=N_
M=]UT;=^GK-^VVMV;',[:W-EX7=WO\U\`CK'KW=M<G>`RK,>IQ-8"'M;"_<TQ
M#=0T;-KH&N&_:M7OO:\$S>#_K;KT3.!;7,'5]L`8'KP/GK7TW;FWF\W!2EF;
MB]Z$S>%2#:^K/>'Y[=Y&O=W/3>+>;<'XUN'^?#K_J]":6<LZ?M77?(A+KN)`
M'N*$6]4E^\OP[=9CC.1K*KX>6N4VO;(9'>7QZMQL/+8SKN6<V<T^_N5HCIIF
MK>/NF+0MSLM43;F3W+40WN:YW.#^8EZ]>E[9E*WA@6ZW++[F!BO2,E[H-TOD
M:.[DWRV9?YY>;.[+]R?GAAYC\MWF&]W6.1[I<ZK=G,[EGK[G/3[JC^GH?<[7
MH=[!J#SF:WWFIB[IBG[EK![K?RO9M[KI9SWHM'[HCR[&3[W?-PWKMNXB5SSL
M4%[LIY[>J-C:KX[J_BWAT8[=@*C@`)WGRC[ID5?FRBZ0[%WMPO[LV@[(<RS?
M#UA^&[[K_=WMI%[JO7[LEY[A@HO6J%:UJ^[NZC[?\1[<J[;CXL[4[.[FWT[@
M4W[1Q<OLO)KNUZ[F]VZJJ<[G?X?;<S[@`2_PH/[N$F_NAKWB\-ZS_BZUXKWP
MT_WD"E_^Z?0N\FJMYY:.\1^_[XQ.?1^.YP./[`R?[]S-WY]L/QO?\`#OTW<.
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M;_/Q7__YB(3&_LP6;__\+V8I=NL``4#@0(("GQQ$F/!)088-'3Z$&%'B1(H5
M+5[$F%'C1HX=/7X$&5+D2)(E39Y$F5+E2I8M7;Z$&5/F3)HU;=[$F1.B0IX]
M??X$JE`G0:`BBPY%FE3I4J9-G3Z%&E7J5*I5K5[%FE7KUJ!=O7Y-^K/@UX0.
MCVY%FU;M6K9MW;Z%&U?N7+IU[9XDFU?O0:1BQ^[ER]#O7<*%#1]&G%CQ8L:-
M'3^>"UART*&#B4Y>^+<G9,Z=/7_^!AU:]&C2I4V7Q)Q:J$Z?9GDVM#RP]6G:
MM6W?QIU;]V[>O2.J!IX9YVS8KUVOUFS<]W+FS9T_AQY=^O2.P56SWGR\;''E
MR;=3!Q]>_'CRY<V?KVH]-?;NWO4^)(Y>_GSZ]>W?QQ]>/6;VR`7OE2@^]ZS+
MKT`##T0P00471&F_R?K[[C_`=LH.``?)8C!##3?DL$,/H;MPPIP$O,P_@TB4
M;;,0W_NP11=?A#%&&=M:D<41*QR0N_9.?*U&&V<$,D@AAR2RR)!\Q!#""%,T
MD<DFQ4(R+R.GI+)**Z_\,$JO^B(1QQ)-]$M+L+`DLTPSST3S.3$IX])++[_\
M;K`UNTK^LTX[[\0SS\3FC.U&%#<ZRT(^^]2S4$,/1331R@;=T<\_+6+324:7
M5+122R_%-%.,)FURT4`IHE-"3A'2M%133T45T5%)=4K*`0GE<57A4J6U5EMO
M!5+665N],$!==\4U6&&');8^7=,#KJ)?@2VV66>?A7:W8[5*<M-?H\4V6VVW
MY6S:SY;E-EQQQR67+6\]`[=<===EMUTE&0TM77?GI;=>>T$ZMS-Y[^6W7W__
MS;?;:_\EN&"#RPT8LGT/9KAAAX--^+&%'X:6`8LOQMABBC=^-F+')N88U8Q'
M)KGDDD-&N52/&P,YY4I-ACEFF35VN>9"5V:L99L+G;EGGT?^WCGH-'%>3&>A
MZ_PY::49.+II*XE6S&BGRURZ:I^GQGI(J/<<..LTK09[9J_'AG%KQ*0FN\BP
MUXXY;;<Y-/LPM-\&DFV[3Z8[[P3C-FQNO6&\._",_R8</[X+\[OP#P5GG&G%
M'T?O<,(2AUS#QAFO///Q)+^+<LT5O%SPST>7CG.[/"?=P-`#3[UUYDRO"W77
M[UN=]=EOQPUVNF3'?;[:[^X]^--TCZQKX1?\W>[CEX]7UN:)9YZZY->.OGJ!
M5WW>>>L/G#[L[;\O6OMOC0??ON[!+C]]Q,5'EWSU?3]_Z??G+QY[T'BGO[GX
ME<Z_?[>@CPO^_->;_25M@`=$"P#^X2)`!.JF@#UK8`2OHL"W,%""MWF@S"ZX
MP:A0\'_NXZ!T,FBR$):0*1ZD$0A-^)P1#FZ%+_34J+)G/QA.IX4UQ.%PV*<O
M%>90?^?S81!K@D)S]5"($UF3)SR!EL;Q$%[N\E&JHB05(J[%@AM<5J2JE$4`
M#8N+=^)B8&+(J1G*$(R]ZDT8^?,B-89H>/NA2ANUJ#4Y?DHF553+%;/$)]/4
MT4%[\^.<KC?%L`3252XR9!=A@L>TZ'%#-!QD(MTH'TDR\BE/M$DE'Y0A3:ZG
M)9;DBA&)M$.N=5),X#&E&M?'QYFD,ED%<B6!4@)*:HE22+1L2BPGM1Q=&G)W
MNW1)+^'^2$EA_A$UI%28+8.$RT(6$YBV<:8F%_C,!D43C>*QYHI&PLP)*C-7
MR`Q@-L&93'&:,H68/&8YKQD==4;Q(]RTBB,Y.<XBMI.>9[-G+*U(S2/ELT;.
M\2<A`77/\,&3/@9=9$#EB16%"C.!_*Q.0]TI+8D*U%J0=")!EZG1>%;TBY/S
M:#%KB4Z.A-2BM#'I*2^"T*DL=$$LG65*/RH7F4:3H1!=:4U/.AJ=KDE9',4G
M3,\CU'3VU*7O,JHK.TI22"5UIQEUZE-%1<;[>7-&1#5*5&?Z4*TZ,XXX_4U7
MI<HRL?J40AB-I!FOA-5WEG6K-W6K2#L(5NW$]9_DM*N6X`/^5+E9549L+6E>
MW]I2P<KUDG1]56&-65#%JA1.B,V97V,$6(TT-HM+M:PN#\O4J69VDJ7TK%XE
M!5G&HG5*E,UI:"5[$]5J-I>(;2V2@AI;T:)6*4<%I&EYU<O`&A8JM%7J"<$*
MW+%.D[@-+2-5U\I7UG;R):G\;3Y[:T_A,O6XHOWE=9%;5=M2I[MG#:2CPKM;
MZ`[1MV,4Y&BUJ\WZ2;>SGDTN:3>JVV;*\;5^).]X[VO.^K)2DEGUJG'/V\^X
MQI>S1OJNCL+XU3;N=[#(JF1_DQI,UYXSN`F-JH$'1:8$/Q:W%%[P4CZL0U^B
M-Z4DEF8]4RQ>F6J8E<NE+XHOV\C^$$LXO9W3KXP]*N(5A[+'MVTQ=YE;MB&#
M>,8J7BU+-APU_+)8H7--)%>CS&")NOC&3ROR)X]<P2T[>9T2:["7V]G-'&.V
MR5FILI!C3,<UTZ3+X4RR2M@KFC`WUY]2KK.9[;M/]XZOPR#*LISCC.815U8]
MM<FSFZF+Y!I3><]<5J>5S0ICM2+UP-D--%ZNDYM&*[J<`E:EHT/=7FM*VK%8
M;G-,!DWC3)MDDVE\,(9MBNE85S?1L2NUFBN]Q587===][;6OY^B;6AO9H3@>
M]6:3W;<`^SG8CWPV@5.-ZVFK&E:O*S2H!GRZ3MNZV\"N</O^K*9HXZO<>)9O
MF=XLZPO^SS;;YOXVD_6I:^6B^M>>OG=I+UVG=X>UW?+N=T3C'=GR.KO:?SVW
MP.L-YH-C*>!UC3!>5[V26Z=UR@;/=Y$HFW`^+SQ/#U?PQ2V><3L76^(EQKC'
M3\MQ0Y.<X.DVT\0]\N.1JUS,+H?JF<7-<@1M'.?Z7K*A9*YPG=/[Y]9>=VE$
MGG.;:YSGJ6WZQQKN<*&BG#1)-R_6^UCTF@?=WE$WMM>-/FFA5[V.T!PZ20:.
MTD?O?.IL?'I3P2[UN:,I[2U?.YU![BNMHSWO0(<YPM\N[!>;^JZJBKN_3<[3
MN\.[\0SO.^#WS>:C"[KN9+U\S!,/WL>[N_(4CSRG0P_:P;?^"+"?E_RI;[;Y
MO78>X*B/J>N9'GAFCQN@K%?\Y$]>^-67OJVVAS#N<R_\UV<>W+[W$%N1#]))
M*4)1Q$_LE8DM^XL"O^/&KSWTYZ-\V)->[+WOON.QOW7MOW?\NK$^OI</M_)'
M'[N,/S^EX__[\,-__3/?>^K)/GO=S[?^`*:]XN,]\)L__+L__AM`=CM`\OL_
M6FO`#N&^`F0^"5RY!80Z"AP[Z4.Z]+N^`)Q`"WRI]G,_V;JZ!ZQ`$\0[#$RY
M[U-`%60[$&0T%YPG&,P(&K2P_AN:]N/`X)/!&LR_E^O!&T1!#3F](82S(/0_
M)-0V&P1"#P1`)C2\B7([(V20(E3^PAA,0#V!J1T4-2<4/RIDP"MD-1$T#RL4
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M'$NA=#6DI$F[!$NEE$-B;,NL+`_@.SNY7+9!K$NVM$?`I"GM^TK]4[VNT\M&
M5$R<'$P@*S.Q/$RT'"B^7,R`;$P!],M<Y$QL=,M$O,R6_"_^P\Q,S4Q+UKQ%
MQ-3'T?0^UX0TO.2-'2RXQ(PXS%S-E-Q*2X/-N_S-;Y1-5+1-BBK.0#RV"^0M
MWNQ-MQQ.':--Y4S.[)M,;RO-,CS.37Q.65K$[F3*6@Q-Y#3+SYS-\73,:SS!
MZV1.\)0,YW1/W]Q.XBS/\'Q-]82\ZIP.+HS/5Z++_@S&["2UJAP^]NQ(]`3-
MZ;1)`;5(`%4D0GNRHY1/_53-X!Q*!&6G^=2RZ)Q"!8U-!SVD_VQ.E+10X630
M/R304$S1$J10X(S,R1I($'U/$DW-VIS0$P6U%84X'#W0%RU''D6E?911A/S.
M&N5'#+U0_"S*^K1/!%12T03276S^4>X<TBVA1JL[2R15.PW52K4TSQXM47S4
M4AAMT2H=DROENA_UT"6,4IX,T[ULTX7441&=4\/Y13,-%3=MTORJ4_'TT3=Z
MR"^USCXE,R[UNRC%4SN"3PXUS1LU4"%<4ZM\5#F-U$5]4S(%TD1ME`J=TDPB
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M_-I1?-J@-5S2+%O%=;JI_=FC]5O+)=B(%=S`[=+([5C.)<+^PIW<5,7;O%5;
MTNW0M=U9Q$580;6QP0U2SZ3=^\#:K&7=]G3=^_39SV5<"9W+\SQ=PK7=VS46
MV)6VU=5<I=/$X67;XE5:T%5%)D7>;L5<>ZW:[/77W5W<W.U9V55=ZLT=TR5?
M@.1>?5W9]/54587>M7S?:+W>#`U4Y87,YA73D[7?:67/N/3=^)7<WIU!+Q5?
M\BC@6UW?U!U9Z?5?^&T[)\7?Y#-?T95,!6[*``W>M+W=!N[+I;O?ATW"[7U@
M6`1?X:7@UY5>2!7@S=W?':4Y!P;A;TI@([VE`Q9;`%[>^<57$CS5%JY8_OK?
MWQTED_TT]K-AMQUA[4UA/15BN#W^8=W-30B.X:LB0W&\6/9E4RS-W"F^XB6.
ME<)LVGB5XB:NX8#55$I1X?-%X=/4237F4R\N5S#.UED+8L^]7`$]XVH!7"P^
MUC1MXPS.RPB.71SNPERKXWP-8</-XU<S83[^8B`&7BZ&W'[UX/#=MOQTXUV]
MSD7>-`1FU$OF7QVV9!ZV5C\NY#'K7#).Y!7>6DY^4'H%Y`8-M[*,Y5,6Y%`V
MY3<.J.AMVYO-5%?VR1M^XAZ>MPOV7AA&9&'.96(&UT,&9CV.9%6.YF=^9;F5
MX]#-)B2&XQV.RE*FX75,,V>FYC.EY?D=YV">YA*6Y2(VYEM.95)6-DBVYI[B
MY7-6U%?^9>7$M><9+>=EUN8^2V=XQC:\;3;UQ2]15N9]YF<ESN<D56AHQF4M
M#FAVGNC#0]]:7C3>K5&$;M^']L\_YNA1]6ARQN<7?D*=^N=CQN1M5M%GMD:+
M'>.1SE.09NE8E>D?&60Z=N&R2FEW%F>87F!.[F.+CNF;OC83K661-NHW^=`S
MCN-D=F@[AEH+?N0\MFE)#N"EME*:;NB(UNJ9-F@\_>%NYFJ55E>SWF('E52H
M=MBOOF>D#FFE=NMABVKW?.G%JNA>'NA,UM0LQNK1G>MZE-H,#NR/;NK^'&J@
M9FBT[F"?3NCN7&>VEM_"/NK!#FG*9LF<?LZKEFK-_FN)K&G^KP1/T9;F_,5L
M-#YLQE[CTU[HU#[,`I7LDP[MQHUKC8;*S51MOF5MU(;K;=YM=';MC/3KS@[K
MKI97X^[HL6QELC[KWQ8CKW9LV5;6KEIL*Q[NV,[AV=[CW);9@V1AYCYNYW[N
MDH[NU4YJW`;EN@ZM1BUMR]9N#7[OY88OZ<9N2A5O9BEN[K[N3#9OB?9LR_I>
MX@[N]I[D\V[-S.IM`3=8UNYGY*9.1S[P@:UNP>IOO9YP`M?DVJ;O`LMO@?Y@
MS&YP_6[I^'[L80YP#O]N"R_K\D9F#_]5%/]O%?_PN<YKQ4YK%K=O$Y?OFDIP
M%X?NSW9>JM[P(+MP&9_QKZ[Q+PO^<0?/<6?E\0XW<O(&\JXE<2F/T'8&[]:E
M\7G&<<J$\")/X9!:<AL'<Z(N6?Y6[X)V8A^G2B3O[BG?<0P'5!T?\%D>\T/K
M7C:'V2Z?Q6R>73+W(3U?<3YO<3GG\MUD9B+]<^\<JBRG<D3'YLP^HJR&\PPG
M7W^>="DEY$R7830/:@W?;T#G=-05]%%7MR]/=$,W]55G]<!$]?$%]5:7]5E7
M6":GVEBG]5S7=6Z.<N/U]%T']F!?=%4_\U\7]F-']IXF]KTV\&1W]F?'<@6O
M76.']FJW]@JO;W(3\FOG]FZ/<T>G7%SW]G$G=]M>]F)O]G)7]W6_:S,GIFUG
M]W@O]U?^]V01E_=[Q_<(KW1F%_=\]W=K]V%P/O=_)_B"/W%[KV>\-OB%9_@Z
MSW9^[_>&EWA9#_CDIO:)QW@<4F>(??B,]WB,WWC3WO>/)WF#/^*03?>25_D:
MHO,@#_F5AWE=?]R0G/F8MWF"W_0VI_>;Y_GJN>;RS?F>%_IU3^(";_FA1_IK
MQW0M?_FD=_HCJN0CO_BGI_KO@?3P_OFJUWIYC^(FE_"M!_M\%V-.]>^P-_MX
M%Z=`[OJS9WNT#^<DE^>VEWNWOV]&G_N[I_NZ7R.\Y_M[UWM&[OO`9_>_AVC!
M-WRB)_S*/OS%]_;$[Q3&AWQU3_S(IWQ_O^_*QWR<!_',Y_P_@G?KS@=]AI?I
MT"?]B1_GTD?]C^_KU&=]F`?0UH?]H5?NV*=]K0>NVL?]NV?5W.?]R-^QW@=^
+W+_ZX"=^I@@(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
